We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$560M
AUM Growth
-$89.7M
Cap. Flow
-$54.1M
Cap. Flow %
-9.65%
Top 10 Hldgs %
99.7%
Holding
17
New
1
Increased
–
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$2.27M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$52M
2
NVRO
NEVRO CORP.
NVRO
+$3.31M
3
VSTM icon
Verastem
VSTM
+$1.02M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
2 Miscellaneous 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
1
DELISTED
Radius Health, Inc.
RDUS
$359M 64.04%
5,831,253
– –
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
$111M 19.84%
5,681,544
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$27.7M 4.94%
1,729,674
– –
TARA icon
4
Protara Therapeutics
TARA
$233M
$15.3M 2.72%
24,585
– –
ALT icon
5
Altimmune
ALT
$665M
$12.1M 2.15%
21,159
– –
TRIV
6
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$11.8M 2.11%
1,776,692
– –
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$10.1M 1.81%
150,000
-61,884
-29% -$3.31M
PETX
8
DELISTED
Aratana Therapeutics, Inc.
PETX
$6.24M 1.11%
1,117,875
– –
HSTO
9
DELISTED
Histogen Inc. Common Stock
HSTO
$3.43M 0.61%
5,960
– –
AVTX icon
10
Avalo Therapeutics
AVTX
$1.03B
$2M 0.36%
+207
New +$2.27M
SVRA icon
11
Savara
SVRA
$1.1B
$1.07M 0.19%
36,455
– –
SGMO
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$205K 0.04%
22,487
– –
CLCD
13
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$183K 0.03%
21,806
– –
ETRM
14
DELISTED
EnteroMedics Inc.
ETRM
$145K 0.03%
1,060
– –
MGNX icon
15
MacroGenics
MGNX
$280M
$98K 0.02%
3,168
– –
VSTM icon
16
Verastem
VSTM
$743M
– –
-47,740
Closed -$1.02M
PTLA
17
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-1,220,672
Closed -$52M

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, MPM Asset Management held 17 positions worth $560M, down 14% from $650M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management withdrew a net $54.1M in Q4 2015, closing 2 positions and reducing 1 holding. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, MPM Asset Management opened a new position in Avalo Therapeutics worth $2M.

  • MPM Asset Management's largest Q4 2015 buy was Avalo Therapeutics: 207 shares worth $2M.
  • MPM Asset Management's biggest Q4 2015 reduction was NEVRO CORP., cutting an estimated $3.31M.
  • MPM Asset Management fully exited Portola Pharmaceuticals, Inc. in Q4 2015, selling an estimated $52M.
  • MPM Asset Management's ten largest holdings make up 100% of its $560M portfolio in Q4 2015.
  • MPM Asset Management opened 1 new position and closed 2 in Q4 2015.
  • MPM Asset Management's portfolio value fell 14% quarter-over-quarter to $560M.

Based on MPM Asset Management's 13F filing for Q4 2015, filed 4 Feb 2016.